Trial reportAnnals of surgery1998
Growth hormone treatment in pediatric burns: a safe therapeutic approach.
Trial report in Annals of surgery, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Effects of growth hormone and anabolic steroids, in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Safety and effectiveness of propranolol in severely burned patients: systematic review and meta-analysis.World journal of emergency surgery : WJES · 2017Pooled it
- Recombinant human growth hormone for treating burns and donor sites.The Cochrane database of systematic reviews · 2014Pooled it
- Randomized controlled trial to determine the efficacy of long-term growth hormone treatment in severely burned children.Annals of surgery · 2009Trial
- Beneficial effects of extended growth hormone treatment after hospital discharge in pediatric burn patients.Annals of surgery · 2006Trial
- Beta-blockade and growth hormone after burn.Annals of surgery · 2002Trial
- Attenuation of posttraumatic muscle catabolism and osteopenia by long-term growth hormone therapy.Annals of surgery · 2001Trial
- Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment.Annals of surgery · 1999Trial
- Update on Hypermetabolism in Pediatric Burn Patients.Seminars in plastic surgery · 2024Review
- Nutrition in Pediatric Burns.Seminars in plastic surgery · 2024Review
- A Reappraisal of Oxandrolone in Burn Management.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2022Review
- Glucose Metabolism in Burns-What Happens?International journal of molecular sciences · 2021Review
- Burn Serum Stimulates Myoblast Cell Death Associated with IL-6-Induced Mitochondrial Fragmentation.Shock (Augusta, Ga.) · 2017Article
- Elevations in growth hormone and glucagon-like peptide-2 levels on admission are associated with increased mortality in trauma patients.Scandinavian journal of trauma, resuscitation and emergency medicine · 2016Observational
- Burns in children: standard and new treatments.Lancet (London, England) · 2014Review
- Burns: an update on current pharmacotherapy.Expert opinion on pharmacotherapy · 2012Review
- Production of human growth hormone in transgenic rice seeds: co-introduction of RNA interference cassette for suppressing the gene expression of endogenous storage proteins.Plant cell reports · 2012Article
- The GH/IGF-1 system in critical illness.Best practice & research. Clinical endocrinology & metabolism · 2011Review
- What, how, and how much should patients with burns be fed?The Surgical clinics of North America · 2011Review
- Microfluidics for T- lymphocyte cell separation and inflammation monitoring in burn patients.Clinical and translational science · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo determine the safety and efficacy of recombinant human growth hormone (rhGH) in the treatment of children who are severely burned. SUMMARY BACKGROUND DATA: During the last decade, we have used recombinant human growth hormone (rhGH; 0.2 mg/kg/day s.q.) to successfully treat 130 children with more than 40% total body surface area (TBSA) burns to enhance wound healing and decrease protein loss. A significant increase in the mortality of adult patients in the intensive care unit who were given rhGH has recently been reported in two large European trials which questions the therapeutic safety of rhGH.
methodsThe records of 263 children who were burned were reviewed. Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82) were compared with randomized placebo-administered controls (n = 54), contiguous matched controls (n = 48), and matched patients admitted after August 1997, after which no patients were treated with rhGH (n = 31). Morbidity and mortality, which might be altered by rhGH therapy, were considered with specific attention to organ function or failure, infection, hemodynamics, and calcium, phosphorous, and albumin balance.
resultsA 2% mortality was observed in both rhGH and saline placebo groups in the controlled studies, with no differences in septic complications, organ dysfunction, or heart rate pressure product identified. In addition, no difference in mortality could be shown for those given rhGH therapeutically versus their controls. No patient deaths were attributed to rhGH in autopsies reviewed by observers blinded to treatment. Hyperglycemic episodes and exogenous insulin requirements were higher among rhGH recipients, whereas exogenous albumin requirements and the development of hypocalcemia was reduced.
conclusionsData indicate that rhGH used in the treatment of children who were severely burned is safe and efficacious.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.